Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series.

ABSTRACT:

Objective

To evaluate the effect and safety of topical anti-human vascular endothelial growth factor bevacizumab in dogs with persistent corneal vascularization.

Animals studied

Prospective case series of 15 adult dogs (20 eyes).

Procedures

Dogs received 0.25% bevacizumab eye drops BID for 28 days. Follow-ups were scheduled 28 days and 6-7 months after treatment start. Macroscopic findings were scored for conjunctival hyperemia, chemosis, ocular discharge, corneal edema, vascularization, and pigmentation. Vascularized area was assessed by analyzing photographs using an imaging software.

Results

The treatment response was variable. Some cases showed a marked reduction in vascularized area and edema, while other eyes had subtle signs of improvement. Vascularizati

SUBMITTER: Muellerleile LM 

PROVIDER: S-EPMC9292418 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature